Home > Boards > US Listed > Biotechs > Durect (DRRX)

News: $DRRX DURECT to Present at the 20th

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
whytestocks Member Profile
Member Level 
Followed By 44
Posts 5,380
Boards Moderated 1
Alias Born 06/04/18
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 9/17/2019 10:48:26 AM
DURECT Announces Positive Data from its Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis PR Newswire (US) - 9/17/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/9/2019 1:37:50 PM
DURECT Earns $10 Million Milestone Payment for Further Development of a Long-Acting Injectable HIV Investigational Product Ut... PR Newswire (US) - 9/9/2019 9:29:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 9/6/2019 6:01:44 AM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 9/5/2019 2:44:24 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 9/4/2019 5:50:51 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 9/4/2019 5:28:35 PM
DURECT to Present at the 21st Annual Rodman and Renshaw Global Investment Conference Sponsored by H.C. Wainwright PR Newswire (US) - 9/4/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/13/2019 4:33:55 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/2/2019 2:32:30 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/1/2019 4:18:10 PM
DURECT Corporation Announces Second Quarter 2019 Financial Results and Update of Programs PR Newswire (US) - 8/1/2019 4:05:00 PM
DURECT Corporation to Announce Second Quarter 2019 Financial Results on August 1 PR Newswire (US) - 7/25/2019 4:30:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/23/2019 2:09:16 PM
DURECT and Gilead Enter into License Agreement for Long-Acting Injectable HIV Investigational Product PR Newswire (US) - 7/22/2019 8:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/17/2019 8:31:00 AM
DURECT Announces that the FDA Agreed to File the Full Response to the POSIMIR® Complete Response Letter as a Complete Class ... PR Newswire (US) - 7/17/2019 8:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 7/10/2019 4:27:39 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/27/2019 12:46:16 PM
DURECT Announces Submission to FDA of a Full Response to the POSIMIR® Complete Response Letter PR Newswire (US) - 6/27/2019 8:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/25/2019 4:46:40 PM
DURECT Receives Approval from Nasdaq for Transfer of Listing to Nasdaq Capital Market PR Newswire (US) - 6/25/2019 4:30:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/24/2019 2:13:35 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/21/2019 6:02:08 AM
whytestocks Member Level  Thursday, 05/16/19 04:30:34 PM
Re: None
Post # of 849 
News: $DRRX DURECT to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019

CUPERTINO, Calif. , May 16, 2019 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) announced today that James E. Brown , Chief Executive Officer, and Michael H. Arenberg , Chief Financial Officer, will be participating in the 20 th Annual B. Riley FBR Institutional Investor Confer...

Read the whole news https://marketwirenews.com/news-releases/durect-to-present-at-the-20th-annual-b-riley-fbr-institutional-investor-conference-on-may-22-2019-8202078.html

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist